Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 17.2% – Here’s Why

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) shares traded down 17.2% during trading on Monday . The company traded as low as $0.8885 and last traded at $0.9192. Approximately 239,728 shares changed hands during mid-day trading, an increase of 241% from the average session volume of 70,238 shares. The stock had previously closed at $1.11.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold”.

Telomir Pharmaceuticals Stock Down 17.2%

The firm has a market capitalization of $63.22 million, a PE ratio of -3.17 and a beta of -0.25. The firm’s fifty day simple moving average is $1.25 and its 200-day simple moving average is $1.28.

Telomir Pharmaceuticals (NASDAQ:TELO) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.04.

Hedge Funds Weigh In On Telomir Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TELO. Geode Capital Management LLC boosted its stake in Telomir Pharmaceuticals by 14.0% during the 4th quarter. Geode Capital Management LLC now owns 223,549 shares of the company’s stock valued at $297,000 after purchasing an additional 27,519 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Telomir Pharmaceuticals in the second quarter worth $95,000. Raymond James Financial Inc. raised its stake in shares of Telomir Pharmaceuticals by 4,101.9% in the third quarter. Raymond James Financial Inc. now owns 75,340 shares of the company’s stock worth $105,000 after purchasing an additional 73,547 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Telomir Pharmaceuticals during the second quarter valued at $62,000. Finally, XTX Topco Ltd bought a new position in shares of Telomir Pharmaceuticals during the fourth quarter valued at $53,000.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.